Glucagon-Like Peptide-1 Receptor Agonists and Cancer—Reply
In Reply We thank Etminan et al and Harris and colleagues for their thoughtful comments on our recent article.1 Their thoughtful letters raise complementary points regarding statistical interpretation and study design, which we address in turn.
Authors
- Jiang Bian (ORCID: https://orcid.org/0000-0002-2238-5429)
- Jingchuan Guo (ORCID: https://orcid.org/0000-0001-9799-2592)
- Hao Dai (ORCID: https://orcid.org/0000-0002-8418-0744)
Institutions
- Indiana University Health (US)
- Regenstrief Institute (US)
- University of Florida (US)
- Indiana Cancer Consortium (US)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- JAMA Oncology
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1001/jamaoncol.2025.5370
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00